Cargando…

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dominguez-Mozo, Maria Inmaculada, Perez-Perez, Silvia, Villar, Luisa María, Oliver-Martos, Begoña, Villarrubia, Noelia, Matesanz, Fuencisla, Costa-Frossard, Lucienne, Pinto-Medel, María Jesús, García-Sánchez, María Isabel, Ortega-Madueño, Isabel, Lopez-Lozano, Lorena, Garcia-Martinez, Angel, Izquierdo, Guillermo, Fernández, Óscar, Álvarez-Cermeño, Jose Carlos, Arroyo, Rafael, Alvarez-Lafuente, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455689/
https://www.ncbi.nlm.nih.gov/pubmed/32859922
http://dx.doi.org/10.1038/s41598-020-71283-5
_version_ 1783575666492440576
author Dominguez-Mozo, Maria Inmaculada
Perez-Perez, Silvia
Villar, Luisa María
Oliver-Martos, Begoña
Villarrubia, Noelia
Matesanz, Fuencisla
Costa-Frossard, Lucienne
Pinto-Medel, María Jesús
García-Sánchez, María Isabel
Ortega-Madueño, Isabel
Lopez-Lozano, Lorena
Garcia-Martinez, Angel
Izquierdo, Guillermo
Fernández, Óscar
Álvarez-Cermeño, Jose Carlos
Arroyo, Rafael
Alvarez-Lafuente, Roberto
author_facet Dominguez-Mozo, Maria Inmaculada
Perez-Perez, Silvia
Villar, Luisa María
Oliver-Martos, Begoña
Villarrubia, Noelia
Matesanz, Fuencisla
Costa-Frossard, Lucienne
Pinto-Medel, María Jesús
García-Sánchez, María Isabel
Ortega-Madueño, Isabel
Lopez-Lozano, Lorena
Garcia-Martinez, Angel
Izquierdo, Guillermo
Fernández, Óscar
Álvarez-Cermeño, Jose Carlos
Arroyo, Rafael
Alvarez-Lafuente, Roberto
author_sort Dominguez-Mozo, Maria Inmaculada
collection PubMed
description There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein–Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach.
format Online
Article
Text
id pubmed-7455689
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74556892020-09-01 Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab Dominguez-Mozo, Maria Inmaculada Perez-Perez, Silvia Villar, Luisa María Oliver-Martos, Begoña Villarrubia, Noelia Matesanz, Fuencisla Costa-Frossard, Lucienne Pinto-Medel, María Jesús García-Sánchez, María Isabel Ortega-Madueño, Isabel Lopez-Lozano, Lorena Garcia-Martinez, Angel Izquierdo, Guillermo Fernández, Óscar Álvarez-Cermeño, Jose Carlos Arroyo, Rafael Alvarez-Lafuente, Roberto Sci Rep Article There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein–Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach. Nature Publishing Group UK 2020-08-28 /pmc/articles/PMC7455689/ /pubmed/32859922 http://dx.doi.org/10.1038/s41598-020-71283-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Dominguez-Mozo, Maria Inmaculada
Perez-Perez, Silvia
Villar, Luisa María
Oliver-Martos, Begoña
Villarrubia, Noelia
Matesanz, Fuencisla
Costa-Frossard, Lucienne
Pinto-Medel, María Jesús
García-Sánchez, María Isabel
Ortega-Madueño, Isabel
Lopez-Lozano, Lorena
Garcia-Martinez, Angel
Izquierdo, Guillermo
Fernández, Óscar
Álvarez-Cermeño, Jose Carlos
Arroyo, Rafael
Alvarez-Lafuente, Roberto
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title_full Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title_fullStr Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title_full_unstemmed Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title_short Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
title_sort predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455689/
https://www.ncbi.nlm.nih.gov/pubmed/32859922
http://dx.doi.org/10.1038/s41598-020-71283-5
work_keys_str_mv AT dominguezmozomariainmaculada predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT perezperezsilvia predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT villarluisamaria predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT olivermartosbegona predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT villarrubianoelia predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT matesanzfuencisla predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT costafrossardlucienne predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT pintomedelmariajesus predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT garciasanchezmariaisabel predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT ortegamaduenoisabel predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT lopezlozanolorena predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT garciamartinezangel predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT izquierdoguillermo predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT fernandezoscar predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT alvarezcermenojosecarlos predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT arroyorafael predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab
AT alvarezlafuenteroberto predictivefactorsandearlybiomarkersofresponseinmultiplesclerosispatientstreatedwithnatalizumab